News | March 31, 2026
Novo Nordisk India sets patient-centred price of Rs. 202/day for starting dose of Ozempic and Wegovy
Price of the starting dose of Ozempic and Wegovy reduced by 36% and 48% respectively
Price of the starting dose of Ozempic and Wegovy reduced by 36% and 48% respectively
The presentations underscore the company’s deep expertise in dermatology and immunology
The findings were presented as a late-breaking study at the 2026 American Academy of Dermatology
The approval covers pediatric patients without a matched sibling donor for stem cell transplant
IntraSight Plus enables confident decision-making and better patient care,” Philips said, emphasizing efficiency, simplicity, and precision
Beyond clinical trials, real-world evidence is adding weight to AbbVie’s claims
The move leverages Novartis’ deep expertise in IgE biology and long-standing presence in allergic disease treatments
High-level results from the Phase III OBERON and TITANIA trials revealed that the first-in-class monoclonal antibody reduced the annual rate of moderate-to-severe COPD exacerbations compared with placebo
Otsuka will pay $700 million to Transcend shareholders at closing, with an additional $525 million in contingent payments tied to future sales milestones
Since launching, the hospital has performed over 40 intestinal transplants, including 21 in 2025 alone
Subscribe To Our Newsletter & Stay Updated
